Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
New England Journal of Medicine · 03.10.2024 · 391 (13) · 1179-1192
DOI: 10.1056/nejmoa2407001 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 03.10.2024. Verfasst von Linda-Gail Bekker und 40 weiteren Autor:innen. Beteiligte Einrichtung: From the Desmond Tutu HIV Centre (L.-G.B., K.G., G.N., Y.S.) and the Department of Medicine, Vuka Research Clinic (A.M.W.), University of Cape Town, …. Hauptthemen laut MEDLINE: Anti-HIV Agents, Emtricitabine, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, HIV Infections. Die Arbeit wurde bisher 568-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Desmond Tutu HIV Centre (L.-G.B., K.G., G.N., Y.S.) and the Department of Medicine, Vuka Research Clinic (A.M.W.), University of Cape Town, Cape Town, the Department of Epidemiology and Prevention, Centre for t…
ORCID-Profile: Linda-Gail Bekker, Quarraisha Abdool Karim, Leila E Mansoor
Förderung
- Gilead Sciences
Zitieren
APA
Bekker, L. G., Das, M., Abdool Karim, Q., Ahmed, K., Batting, J., Brumskine, W., Gill, K., Harkoo, I., Jaggernath, M., Kigozi, G., Kiwanuka, N., Kotze, P., Lebina, L., Louw, C. E., Malahleha, M., Manentsa, M., Mansoor, L. E., Moodley, D., Naicker, V., …, & PURPOSE 1 Study Team (2024). Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. New England Journal of Medicine, 391(13), 1179-1192. https://doi.org/10.1056/nejmoa2407001
Vancouver
Bekker LG, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, et al. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. New England Journal of Medicine. 2024;391(13):1179-1192. doi:10.1056/nejmoa2407001
BibTeX
@article{Bekker2024,
author = {Bekker, Linda-Gail and Das, Moupali and Abdool Karim, Quarraisha and Ahmed, Khatija and Batting, Joanne and Brumskine, William and Gill, Katherine and Harkoo, Ishana and Jaggernath, Manjeetha and Kigozi, Godfrey and Kiwanuka, Noah and Kotze, Philip and Lebina, Limakatso and Louw, Cheryl E and Malahleha, Moelo and Manentsa, Mmatsie and Mansoor, Leila E and Moodley, Dhayendre and Naicker, Vimla and Naidoo, Logashvari and Naidoo, Megeshinee and Nair, Gonasagrie and Ndlovu, Nkosiphile and Palanee-Phillips, Thesla and Panchia, Ravindre and Pillay, Saresha and Potloane, Disebo and Selepe, Pearl and Singh, Nishanta and Singh, Yashna and Spooner, Elizabeth and Ward, Amy M and Zwane, Zwelethu and Ebrahimi, Ramin and Zhao, Yang and Kintu, Alexander and Deaton, Chris and Carter, Christoph C and Baeten, Jared M and Matovu Kiweewa, Flavia and PURPOSE 1 Study Team, PURPOSE 1 Study Team},
title = {Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women},
journal = {New England Journal of Medicine},
year = {2024},
volume = {391},
number = {13},
pages = {1179--1192},
doi = {10.1056/nejmoa2407001}
}
EUVIMED